<DOC>
	<DOC>NCT01665430</DOC>
	<brief_summary>This multicenter, open-label, single arm long term extension of study WA19926 will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with early, moderate to severe rheumatoid arthritis who have completed the WA19926 core study. Eligible patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for up to 104 weeks.</brief_summary>
	<brief_title>A Long-Term Extension Study to WA19926 of RoActemra/Actemra (Tocilizumab) in Patients With Early, Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Patients who complete WA19926 core study (visit at Week 104 and two followup telephone visits) and who may benefit from study drug treatment according to the Investigator's assessment No current or recent adverse event or laboratory finding preventing the use of the study drug dose of RoActemra/Actemra 8 mg/kg at baseline visit Receiving treatment on an outpatient basis Females of childbearing potential must agree to use at least one adequate method of contraception as defined by protocol during the treatment period Pregnant women Patients who have prematurely withdrawn from the WA19926 study for any reason Treatment with any investigational agent or cell depleting therapies since last administration of study drug in the WA 19926 core study Treatment with an antitumor necrosis factor (TNF) or antiinterleukin (IL)1 agent, or a Tcell costimulation modulator since the last administration of the study drug in the WA19926 core study Immunization with a live/attenuated vaccine since the last administration of study drug in the WA19926 core study Diagnosis since visit at Week 104 of the core WA19926 study of rheumatic autoimmune disease other than rheumatoid arthritis Diagnosis since visit at Week 104 of the core WA19926 study of inflammatory joint disease other than rheumatoid arthritis Evidence of serious uncontrolled concomitant disease or disorder Known active or history of recurrent infection Current liver disease as determined by Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>